VTV

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Retrieved on: 
Wednesday, February 28, 2024

Additional information regarding the composition of the Board is available in a Current Report on Form 8-K filed with the SEC.

Key Points: 
  • Additional information regarding the composition of the Board is available in a Current Report on Form 8-K filed with the SEC.
  • vTv expects to use the proceeds from the PIPE to fund the first Phase 3 study of its lead product candidate, cadisegliatin, which is expected to initiate in mid-2024.
  • JDRF is the world’s largest nonprofit funder of T1D research focused on accelerating cures, preventing, and treating T1D.
  • There are more than 18 million people living with T1D worldwide with fewer than 30% meeting their A1c targets, demonstrating the clear need for additional therapies.

Visit Temecula Valley Announces 2024 Board of Directors, Welcomes New Members

Retrieved on: 
Tuesday, January 9, 2024

TEMECULA, Calif., Jan. 9, 2024 /PRNewswire-PRWeb/ -- Visit Temecula Valley (VTV), the region's official destination tourism and marketing organization, today announced its 2024 Board of Directors, which includes newly appointed and reappointed leaders who will help guide the organization through the year ahead.

Key Points: 
  • The Visit Temecula Valley Executive Committee and Board of Directors for 2024 includes noteworthy community leaders with a passion for the Temecula Valley.
  • TEMECULA, Calif., Jan. 9, 2024 /PRNewswire-PRWeb/ -- Visit Temecula Valley (VTV), the region's official destination tourism and marketing organization, today announced its 2024 Board of Directors, which includes newly appointed and reappointed leaders who will help guide the organization through the year ahead.
  • "This group is critical in terms of driving the strategy behind Visit Temecula Valley's programs and supporting the hospitality industry in our region," said Michael Feeley, Board Chairman.
  • "I look forward to another year of working closely with the Board as we continue to position Temecula Valley as a premiere travel destination."

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments.
  • Cash Position: The Company’s cash position as of September 30, 2023 was $8.2 million compared to $12.1 million as of December 31, 2022.
  • Net Loss: Net loss attributable to vTv shareholders for the three months ended September 30, 2023 was $6.7 million or $0.08 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $4.3 million or $0.05 per basic share.

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, November 2, 2023

as Chief Medical Officer, effective immediately.

Key Points: 
  • as Chief Medical Officer, effective immediately.
  • “I am pleased to welcome Dr. Strack to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics.
  • Most recently, he served as Chief Medical Officer of Faeth Therapeutics Inc., a clinical stage developer of metabolic oncology therapies.
  • He also served as Consultant in Medical Affairs at Omeros Corporation, a clinical stage biopharmaceutical company focused on small-molecule and protein therapeutics for immunologic disorders.

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Retrieved on: 
Wednesday, November 1, 2023

“The proceeds from the sale of our Reneo stock will provide vTv with important financial support as we continue our preparations for the launch of the cadisegliatin Phase 3 program in T1D.

Key Points: 
  • “The proceeds from the sale of our Reneo stock will provide vTv with important financial support as we continue our preparations for the launch of the cadisegliatin Phase 3 program in T1D.
  • We remain in active discussions related to the financing, partnering and/or licensing of cadisegliatin,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics.
  • “We are excited about the therapeutic potential of mavodelpar and look forward to Reneo’s upcoming data readout.
  • Reneo’s lead program, mavodelpar, is a PPARδ agonist currently being studied in a pivotal Phase 2b clinical trial in adults with primary mitochondrial myopathies (PMM).

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Friday, August 11, 2023

HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  • Cash Position: The Company’s cash position as of June 30, 2023, was $12.6 million compared to $12.1 million as of December 31, 2022.
  • Net Loss: Net loss attributable to vTv shareholders for the three months ended June 30, 2023, was $5.6 million or $0.07 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $3.2 million or $0.04 per basic share.

Janus International Group Appoints Roger Fradin as Vice Chairman

Retrieved on: 
Wednesday, July 5, 2023

Janus International Group, Inc. (NYSE: JBI) (“Janus” or the “Company”), a leading provider of cutting-edge access control technologies and building product solutions for the self-storage and other commercial and industrial sectors, today announced the appointment of Roger Fradin to the position of Vice Chairman of the Board of Directors, effective July 5, 2023.

Key Points: 
  • Janus International Group, Inc. (NYSE: JBI) (“Janus” or the “Company”), a leading provider of cutting-edge access control technologies and building product solutions for the self-storage and other commercial and industrial sectors, today announced the appointment of Roger Fradin to the position of Vice Chairman of the Board of Directors, effective July 5, 2023.
  • Mr. Fradin, who has served as a director of Janus since 2021, has over 40 years of experience acquiring, building and leading a diverse set of industrial technology businesses.
  • Mr. Fradin currently serves as Chairman of Resideo Technologies, Inc. (NYSE: REZI) and sits on the boards of L3Harris Technologies Inc. (NYSE: LHX) and Vertiv Group Corp. (NYSE: VTV).
  • Ramey Jackson, Janus’s Chief Executive Officer, said, “I am excited for Roger to be assuming the additional responsibilities of the Vice Chairmanship at Janus.

Secretome Therapeutics Appoints Deepa Prasad as Chief Financial Officer

Retrieved on: 
Monday, June 26, 2023

Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment of underserved diseases, today announced the appointment of Deepa Prasad as Chief Financial Officer.

Key Points: 
  • Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment of underserved diseases, today announced the appointment of Deepa Prasad as Chief Financial Officer.
  • "Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry," said Vinny Jindal, President and Chief Executive Officer of Secretome Therapeutics.
  • I believe that secretomes represent a true breakthrough in the field of cell-based therapy, and I look forward to helping Secretome transform the way we treat diseases," said Ms. Prasad.
  • Previous to vTv, she was General Partner at WestRiver Group where she led healthcare investments in numerous companies, including Design Therapeutics.

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Retrieved on: 
Friday, June 16, 2023

Azeliragon, a small molecule receptor for advanced glycation end products (RAGE) inhibitor, was originally discovered by vTv and studied as a potential treatment for Alzheimer’s disease.

Key Points: 
  • Azeliragon, a small molecule receptor for advanced glycation end products (RAGE) inhibitor, was originally discovered by vTv and studied as a potential treatment for Alzheimer’s disease.
  • Prior to licensing azeliragon to Cantex, vTv produced a substantial body of clinical data supporting the safety and tolerability of azeliragon, as well as preclinical data demonstrating the potential therapeutic benefit of vTv’s RAGE antagonists on several diseases, including cancer and diabetic complications.
  • “We once again extend our congratulations to our partners at Cantex on the continued strengthening of their IP estate for azeliragon.
  • “We look forward to the results of Cantex's collaboration with Georgetown, which will provide greater visibility into the potential of azeliragon to alleviate cognitive decline caused by chemotherapy.”

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

Retrieved on: 
Wednesday, May 24, 2023

Azeliragon is a small molecule inhibitor of the receptor for advanced glycation end products (RAGE) discovered by vTv and licensed to Cantex Pharmaceuticals.

Key Points: 
  • Azeliragon is a small molecule inhibitor of the receptor for advanced glycation end products (RAGE) discovered by vTv and licensed to Cantex Pharmaceuticals.
  • Earlier this year, Cantex received Food and Drug Administration Orphan Drug Designation for azeliragon for the treatment of glioblastoma.
  • On June 22, 2021, vTv and Cantex entered into a licensing agreement under which Cantex obtained exclusive worldwide rights to develop and commercialize azeliragon.
  • Prior to the Cantex agreement, vTv was developing azeliragon for the treatment of Alzheimer’s disease.